News
Public · Published
Key facts: AbbVie, Inc. Q3 revenue $17.404B; Skyrizi approved; lutikizumab success
AbbVie reported third-quarter 2026 revenue of $17.404 billion, up 10.3% year over year, and adjusted earnings per share of $3.82. The FDA approved Skyrizi for a Crohn's disease use, and AbbVie reported positive Phase 3 results for lutikizumab in hidradenitis suppurativa.
Published:
Updated:
What happened
AbbVie reported third-quarter 2026 revenue of $17.404 billion, up 10.3% year over year, and adjusted earnings per share of $3.82. The FDA approved Skyrizi for a Crohn’s disease use, and AbbVie reported positive Phase 3 results for lutikizumab in hidradenitis suppurativa.
Confirmed
Global impact / market context
Revenue growth and rising sales from products such as Skyrizi may help AbbVie offset declining Humira sales, which fell 31.2% year over year. FDA approval permits the specified Skyrizi use in the United States, potentially widening its commercial opportunity, while lutikizumab remains subject to future regulatory steps.
Analyst inference
The article describes both current product growth and efforts to build future immunology sales through an acquisition and clinical results. Those developments could support revenue beyond Humira, but lutikizumab’s commercial contribution is uncertain because the company has not yet reported a regulatory submission or approval.
Analyst inference
What to watch
- Watch whether AbbVie presents lutikizumab trial data at a congress and pursues regulatory submissions, which it says may happen in a later period. Proposed
- Track Skyrizi sales and any European Medicines Agency decision on AbbVie’s filing; broader access could increase product revenue, but timing and outcome remain unknown. Analyst inference
- Watch future reporting on Humira sales and other portfolio segments, which the article says offset Humira’s decline but does not quantify by product. Analyst inference
Evidence
- Original source link unavailable